The Italian Medicines Agency (AIFA) has officially determined that the monoclonal antibody lecanemab, a new treatment for early-stage Alzheimer’s disease, will not be reimbursed by the Italian National Health Service (SSN). According to the official communication released by AIFA, the agency’s Scientific and Economic Commission (CSE) concluded that the drug does not meet the necessary criteria for public funding at this time, citing significant uncertainties regarding its clinical efficacy and the sustainability of the associated costs.
This decision marks a critical development for patients and families navigating the evolving landscape of neurodegenerative disease management. While lecanemab—marketed internationally as Leqembi—has received conditional marketing authorization from the European Medicines Agency (EMA), individual member states retain the authority to determine reimbursement policies based on their own health technology assessments. In Italy, the CSE’s evaluation emphasized that the therapeutic benefit of the treatment, particularly in relation to the risk of serious side effects, did not justify the financial burden on the public healthcare system.
Understanding the AIFA Decision
The core of the agency’s assessment rests on the interpretation of clinical trial data regarding the drug’s ability to slow cognitive decline. The European Medicines Agency (EMA) granted marketing authorization for lecanemab in August 2024, noting that it is intended for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease who have confirmed amyloid pathology. However, the Italian commission’s review process, which focuses on cost-effectiveness and local clinical integration, reached a different conclusion regarding the drug’s value proposition for the Italian population.
The commission specifically highlighted concerns regarding the “benefit-risk profile” of the medication. Lecanemab is known to be associated with amyloid-related imaging abnormalities (ARIA), which can manifest as brain swelling or micro-hemorrhages. These potential complications require intensive monitoring, including regular magnetic resonance imaging (MRI) scans and specialized neurological oversight, creating additional logistical and economic pressures on the healthcare system that the CSE determined were not sufficiently offset by the drug’s modest impact on slowing disease progression.
Clinical Context and Patient Impact
For patients currently seeking treatment for Alzheimer’s disease, this decision means that lecanemab will not be available through the public health system, though it may remain accessible through private channels. The classification of the drug as “non-reimbursable” effectively excludes it from the list of medications covered by the Italian state, meaning patients who wish to pursue this therapy must bear the full cost themselves.
Medical experts emphasize that the treatment of Alzheimer’s remains a multifaceted challenge. Current standard care in Italy focuses on symptomatic management, including cholinesterase inhibitors and lifestyle interventions. The introduction of disease-modifying therapies like lecanemab represents a shift in focus toward targeting the underlying biology of the disease—specifically the accumulation of amyloid-beta plaques in the brain. However, as noted by the Alzheimer Europe organization, the arrival of these drugs has sparked intense debate across the continent regarding how health systems should prioritize spending for chronic, incurable conditions.
Comparing Regulatory Approaches
The divergence between the EMA’s approval and AIFA’s reimbursement denial highlights a common tension in European healthcare policy. While the EMA evaluates safety and efficacy on a continental scale, national bodies like AIFA must balance these factors against the specific budgetary constraints and organizational realities of their national health services.
In other jurisdictions, the reception of lecanemab has been similarly cautious. The United States Food and Drug Administration (FDA) granted traditional approval to the drug in July 2023, following clinical studies that demonstrated a reduction in clinical decline by 27% over 18 months in early-stage patients. Despite this, the United Kingdom’s National Institute for Health and Care Excellence (NICE) initially issued draft guidance expressing concerns over the cost-effectiveness of the drug, illustrating that Italy is not alone in its rigorous scrutiny of these high-cost biologics.
What Comes Next for Patients
There is no immediate path for a reversal of this decision, though AIFA maintains standard procedures for re-evaluating medications should new, compelling data emerge. For families affected by Alzheimer’s, the focus remains on early diagnosis and access to supportive care services provided by the Italian regional health authorities.
Patients are encouraged to discuss the implications of this decision with their neurologists or geriatricians, who can provide context on alternative treatment paths and clinical trials. Official updates regarding the status of pharmaceutical reimbursements in Italy are published regularly on the AIFA website. As the medical community continues to study the long-term outcomes of amyloid-targeting therapies, further data may eventually shift the landscape for future reimbursement discussions.